TARS

Tarsus Pharmaceuticals' stock has been impacted by strong Q1 2026 and Q4 2025 earnings reports, advancements in pipeline programs, insider selling, and overall stock price performance. In Q1 2026, net product sales exceeded $145 million, an increase of over 85% year-over-year. The company reported Q4 2025 net product sales of $151.7 million, contributing to total 2025 net product sales of $451.4 million. Tarsus advanced two pipeline programs in 2026: the Phase 2 Calliope study for Lyme disease prevention (TP-05) and the Phase 2 KORE study for ocular rosacea (TP-04). Insiders have sold approximately $7.9 million worth of stock in the past three months. As of May 1, 2026, the share price was $63.62, a 32.54% increase over the past year.